<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>ALPA</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">ALPA</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="alpa-laboratories-limited" class="section level1">
<h1>Alpa Laboratories Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALPA.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALPA.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALPA.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALPA.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALPA.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALPA.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALPA.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALPA.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALPA.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<p>Based on the comprehensive documents provided for <strong>Alpa Laboratories Ltd.¬†(ALPA)</strong>‚Äîincluding unaudited financial results, auditor‚Äôs review reports, and voting outcomes from the 37th Annual General Meeting (AGM)‚Äîwe provide a detailed <strong>analysis of headwinds, tailwinds, growth prospects, and key risks</strong> for the company, with a summary suitable for investors and market participants.</p>
<hr />
<div id="company-overview" class="section level9">
<p class="heading">üìå <strong>Company Overview:</strong></p>
<ul>
<li><strong>Name:</strong> Alpa Laboratories Limited<br />
</li>
<li><strong>Scrip Code (NSE):</strong> <code>ALPA</code> | <strong>BSE Code:</strong> <code>532878</code><br />
</li>
<li><strong>CIN:</strong> L85195MP1988PLC004446<br />
</li>
<li><strong>Sector:</strong> Pharmaceuticals &amp; Chemicals (Single Segment Operations)<br />
</li>
<li><strong>Listing Requirements:</strong> Compliant with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015<br />
</li>
<li><strong>Head Office:</strong> Indore, Madhya Pradesh, India</li>
</ul>
<hr />
</div>
<div id="financial-performance-highlights-q2-fy26-quarter-ended-sept-2025" class="section level6">
<h6>üîé <strong>1. Financial Performance Highlights (Q2 FY26; Quarter ended Sept 2025)</strong></h6>
<div id="standalone-unaudited-results-rs.-in-lacs" class="section level9">
<p class="heading">‚úÖ Standalone Unaudited Results (Rs. in Lacs):</p>
<table>
<thead>
<tr class="header">
<th>Parameter</th>
<th>Q2 FY26 (Sep-25)</th>
<th>Q1 FY26 (Jun-25)</th>
<th>Q2 FY25 (Sep-24)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenue from Operations</strong></td>
<td>‚Çπ2,563.21 Cr</td>
<td>‚Çπ1,911.07 Cr</td>
<td>‚Çπ2,493.87 Cr</td>
</tr>
<tr class="even">
<td><strong>Total Income (Operations + Other)</strong></td>
<td>‚Çπ2,931.81 Cr</td>
<td>‚Çπ3,106.58 Cr</td>
<td>‚Çπ3,154.53 Cr</td>
</tr>
<tr class="odd">
<td><strong>Total Expenses</strong></td>
<td>‚Çπ1,971.69 Cr</td>
<td>‚Çπ1,929.36 Cr</td>
<td>‚Çπ2,233.03 Cr</td>
</tr>
<tr class="even">
<td><strong>PBT (Pre-Tax Profit)</strong></td>
<td>‚Çπ1,013.13 Cr</td>
<td>‚Çπ1,177.22 Cr</td>
<td>‚Çπ959.39 Cr</td>
</tr>
<tr class="odd">
<td><strong>PAT (Post-Tax Profit)</strong></td>
<td>‚Çπ762.81 Cr</td>
<td>‚Çπ980.79 Cr</td>
<td>‚Çπ762.90 Cr</td>
</tr>
<tr class="even">
<td><strong>EPS (Basic)</strong></td>
<td>‚Çπ3.63</td>
<td>‚Çπ4.66</td>
<td>‚Çπ3.63</td>
</tr>
</tbody>
</table>
<blockquote>
<p>Note: Half-year consolidated PAT dropped to ‚Çπ630.00 Lac vs ‚Çπ1,193.83 Lac YoY.</p>
</blockquote>
<hr />
</div>
<div id="key-observations" class="section level9">
<p class="heading">üìä Key Observations:</p>
<ul>
<li><strong>Revenue growth YoY (Q2):</strong> +2.77%<br />
</li>
<li><strong>Profitability under pressure:</strong>
<ul>
<li>PAT <strong>flat YoY</strong> despite revenue growth.</li>
<li>Sharp decline in <strong>consolidated net profit (PBT)</strong>: ‚Çπ1,118.77 Lac ‚Üí ‚Çπ1,187.72 Lac (Q2 only)</li>
<li><strong>Half-year consolidated pre-tax profit dropped 47%</strong> YoY (‚Çπ1,193.83 Lac ‚Üí ‚Çπ630.00 Lac)</li>
</ul></li>
<li><strong>High Other Income (‚Çπ368.61 Cr)</strong>: Contributes ~13% of total income ‚Äì implies reliance on non-core income (e.g., interest, dividends, grants).</li>
<li><strong>Operating margin squeeze</strong> likely due to rising raw material costs and higher finance cost (‚Çπ46.1 Lac vs ‚Çπ34.3 Lac in consolidated).</li>
</ul>
<hr />
</div>
</div>
<div id="tailwinds-positive-factors" class="section level6">
<h6>üå¨Ô∏è <strong>2. Tailwinds (Positive Factors)</strong></h6>
<ol style="list-style-type: decimal">
<li><p class="heading" id="stable-operational-revenue-with-yoy-growth">‚úÖ <strong>Stable Operational Revenue with YoY Growth</strong></p>
<ul>
<li>Revenue from operations up <strong>2.77% YoY</strong> (‚Çπ2,493.87 Lac ‚Üí ‚Çπ2,563.21 Lac).</li>
<li>Indicates resilience in demand for pharmaceutical and chemical products.</li>
</ul></li>
<li><p class="heading" id="successful-agm-shareholder-approval">‚úÖ <strong>Successful AGM &amp; Shareholder Approval</strong></p>
<ul>
<li>All resolutions passed with <strong>over 99% shareholder approval</strong>, including:
<ul>
<li>Reappointment of directors</li>
<li>Ratification of auditor remuneration</li>
<li>Approval of secretarial auditors</li>
<li><strong>Special Resolution (Section 186 limit increased)</strong> ‚Äì enables larger investments/loans.</li>
</ul></li>
<li>Demonstrates <strong>strong governance and investor confidence</strong>.</li>
</ul></li>
<li><p class="heading" id="robust-cash-flow-from-operations">‚úÖ <strong>Robust Cash Flow from Operations</strong></p>
<ul>
<li>Net cash flow from operating activities (standalone): <strong>‚Çπ1,214.72 Lac</strong> (Q2 FY26)</li>
<li>Positive operational efficiency and collection cycles.</li>
</ul></li>
<li><p class="heading" id="no-material-misstatements-in-auditor-review">‚úÖ <strong>No Material Misstatements in Auditor Review</strong></p>
<ul>
<li>Auditor‚Äôs report confirms <strong>no red flags</strong> in unaudited results.</li>
<li>Independent auditor confirms compliance with <strong>Ind AS 34</strong>, giving credibility to disclosed figures.</li>
</ul></li>
<li><p class="heading" id="no-invalid-votes-full-participatory-integrity">‚úÖ <strong>No Invalid Votes ‚Äì Full Participatory Integrity</strong></p>
<ul>
<li>Transparent e-voting process reported by independent scrutinizer.</li>
<li>High participation: <strong>62 shareholders</strong> cast votes via e-voting.</li>
</ul></li>
</ol>
<hr />
</div>
<div id="headwinds-challenges-concerns" class="section level6">
<h6>üå™Ô∏è <strong>3. Headwinds (Challenges &amp; Concerns)</strong></h6>
<ol style="list-style-type: decimal">
<li><p class="heading" id="decline-in-profit-after-tax-pat-yoy">‚ö†Ô∏è <strong>Decline in Profit After Tax (PAT) YoY</strong></p>
<ul>
<li>Despite revenue growth, PAT remained <strong>flat</strong> YoY.</li>
<li><strong>Operating expenses have increased</strong> ‚Äî cost of materials consumed is higher than revenue growth.</li>
</ul></li>
<li><p class="heading" id="sharp-decline-in-consolidated-profitability">‚ö†Ô∏è <strong>Sharp Decline in Consolidated Profitability</strong></p>
<ul>
<li><strong>Consolidated PBT for half-year 2025-26:</strong> ‚Çπ630.00 Lac vs ‚Çπ1,193.83 Lac in H1 FY25</li>
<li>Suggests <strong>subsidiary (Norfolk Mercantile Pvt Ltd.) is underperforming</strong>, possibly incurring losses.</li>
</ul></li>
<li><p class="heading" id="dependency-on-non-core-income">‚ö†Ô∏è <strong>Dependency on Non-Core Income</strong></p>
<ul>
<li>Other income: ‚Çπ368.61 Lac in Q2, representing <strong>~12.5% of total income</strong>.</li>
<li>If non-core income reduces (e.g., interest earnings), <strong>core profitability may look weaker</strong>.</li>
</ul></li>
<li><p class="heading" id="consolidation-risks-from-underperforming-subsidiary">‚ö†Ô∏è <strong>Consolidation Risks from Underperforming Subsidiary</strong></p>
<ul>
<li>The auditor highlights: &gt; <em>‚ÄúSubsidiary‚Ä¶ had net loss of ‚Çπ(7.28) Lac for the quarter‚Ä¶ cash flows of ‚Çπ51.06 Lac.‚Äù</em></li>
<li>While deemed immaterial now, continued losses could become <strong>a drag on group performance</strong>.</li>
</ul></li>
<li><p class="heading" id="negative-net-cash-flow-from-investing-financing-activities">‚ö†Ô∏è <strong>Negative Net Cash Flow from Investing &amp; Financing Activities</strong></p>
<ul>
<li><strong>Net cash outflow from investing:</strong> ‚Çπ159.25 Lac<br />
</li>
<li><strong>High investments in fixed assets and financial instruments</strong> indicate expansion but could strain liquidity if cash from operations slows.</li>
</ul></li>
</ol>
<hr />
</div>
<div id="growth-prospects" class="section level6">
<h6>üìà <strong>4. Growth Prospects</strong></h6>
<table>
<colgroup>
<col width="40%" />
<col width="60%" />
</colgroup>
<thead>
<tr class="header">
<th>Indicator</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Sector Growth (Pharma &amp; Chemicals)</strong></td>
<td>Favorable long-term outlook due to rising global healthcare demand, especially in emerging markets.</td>
</tr>
<tr class="even">
<td><strong>Geographic Reach</strong></td>
<td>Not detailed, but generic API/chemical focus suggests export potential; needs confirmation.</td>
</tr>
<tr class="odd">
<td><strong>Capacity Expansion</strong></td>
<td>Capital work-in-progress = ‚Çπ0 ‚Üí <strong>no ongoing expansion projects</strong>, limiting future scaling.</td>
</tr>
<tr class="even">
<td><strong>R&amp;D / Innovation</strong></td>
<td>Not disclosed ‚Üí likely focused on <strong>generic APIs</strong>, low-margin but high-volume products.</td>
</tr>
<tr class="odd">
<td><strong>Regulatory Clarity</strong></td>
<td>No adverse regulatory disclosures; compliant with SEBI norms.</td>
</tr>
</tbody>
</table>
<blockquote>
<p>üü° <strong>Opportunities</strong>: - Unlock value via <strong>export tie-ups</strong> or <strong>global certifications</strong> (e.g., USFDA, EU-GMP). - <strong>Optimize subsidiary</strong> performance or consider exit if non-core.</p>
</blockquote>
<hr />
</div>
<div id="key-risks" class="section level6">
<h6>‚ö†Ô∏è <strong>5. Key Risks</strong></h6>
<table>
<colgroup>
<col width="27%" />
<col width="36%" />
<col width="36%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk</th>
<th>Nature</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>1. Declining Consolidated Profits</strong></td>
<td>High</td>
<td>Suggests poor control over group entities or temporary challenges in subsidiary ops.</td>
</tr>
<tr class="even">
<td><strong>2. Flat PAT vs Rising Revenue</strong></td>
<td>Medium</td>
<td>Indicates thinning margins due to pricing pressure or input cost inflation.</td>
</tr>
<tr class="odd">
<td><strong>3. Reliance on Non-Core Income</strong></td>
<td>Medium</td>
<td>Weakens the credibility of recurring profitability.</td>
</tr>
<tr class="even">
<td><strong>4. No Active Expansion Projects</strong></td>
<td>Medium</td>
<td>Limits future growth; may hurt competitiveness.</td>
</tr>
<tr class="odd">
<td><strong>5. Subsidiary Performance Risk (Norfolk Mercantile)</strong></td>
<td>Medium</td>
<td>Small now, but potential future drag if losses continue.</td>
</tr>
<tr class="even">
<td><strong>6. Dependence on Tax Benefits &amp; Deferrals</strong></td>
<td>Medium</td>
<td>Tax expense volatile; deferred tax changes can impact P&amp;L.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="summary-investment-outlook-for-alpa" class="section level6">
<h6>‚úÖ <strong>Summary: Investment Outlook for ALPA</strong></h6>
<table>
<colgroup>
<col width="52%" />
<col width="47%" />
</colgroup>
<thead>
<tr class="header">
<th>Parameter</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Business Model</strong></td>
<td>Pharma &amp; Chemicals (Single segment), standalone revenue stable.</td>
</tr>
<tr class="even">
<td><strong>Financial Health (Short-term)</strong></td>
<td>‚úÖ Strong cash flows, no debt reported, adequate working capital.</td>
</tr>
<tr class="odd">
<td><strong>Profitability Trend</strong></td>
<td>üî¥ <strong>Concerning</strong>: Flat PAT YoY, falling consolidated profits.</td>
</tr>
<tr class="even">
<td><strong>Governance</strong></td>
<td>‚úÖ Excellent: Full shareholder approval, timely disclosures, auditor validation.</td>
</tr>
<tr class="odd">
<td><strong>Growth Potential</strong></td>
<td>üü° <strong>Limited Visibility</strong>: No new capacity or product launches disclosed.</td>
</tr>
<tr class="even">
<td><strong>Valuation (Based on EPS)</strong></td>
<td>EPS of ‚Çπ3.63 (Q2 FY26) implies <strong>annualized ~‚Çπ7.26/share</strong>, suggesting undervaluation if consistent.</td>
</tr>
<tr class="odd">
<td><strong>Overall Sentiment</strong></td>
<td><strong>Neutral-to-Cautiously Optimistic</strong></td>
</tr>
</tbody>
</table>
<hr />
<div id="verdict-hold-with-a-watch-on-profit-margins-consolidation-risk" class="section level9">
<p class="heading">üèÅ <strong>Verdict: ‚ÄúHold‚Äù with a Watch on Profit Margins &amp; Consolidation Risk</strong></p>
<ul>
<li><strong>Buy?</strong> Not yet. Wait for confirmation of stable or improving PAT.</li>
<li><strong>Hold?</strong> Yes, due to solid governance, liquidity, and revenue base.</li>
<li><strong>Sell?</strong> Only if profit margins keep eroding or subsidiary losses escalate.</li>
</ul>
<hr />
</div>
<div id="key-monitoring-metrics-going-forward" class="section level9">
<p class="heading">üìå <strong>Key Monitoring Metrics Going Forward:</strong></p>
<ol style="list-style-type: decimal">
<li><strong>PAT Margin Trend</strong> ‚Äì Watch Q3 and Q4 results for recovery.</li>
<li><strong>Subsidiary Performance</strong> ‚Äì Whether Norfolk Mercantile turns profitable.</li>
<li><strong>Non-Core Income %</strong> ‚Äì Reduce below 10% for credibility.</li>
<li><strong>Working Capital Management</strong> ‚Äì Keep inventory and receivables in check.</li>
<li><strong>CapEx Plans</strong> ‚Äì Any sign of new investment or capacity building.</li>
</ol>
<hr />
<blockquote>
<p>üîî <strong>Final Take:</strong><br />
<em>Alpa Laboratories shows signs of operational resilience and good corporate governance, but its <strong>profitability story needs a turnaround</strong>. Investors should remain <strong>cautious until margins stabilize and the consolidation benefits emerge</strong>. The special resolution for enhanced Section 186 powers may signal upcoming M&amp;A or investment‚Äîmonitor for strategic moves.</em></p>
</blockquote>
<hr />
<p>üì¨ <strong>Disclosure</strong>: This analysis is based on unaudited quarterly disclosures and AGM documents. A full audit and annual report will provide greater clarity.</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
